Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 12:24PM ET
0.3335
Dollar change
-0.0165
Percentage change
-4.71
%
Index- P/E- EPS (ttm)-0.76 Insider Own49.45% Shs Outstand78.51M Perf Week-26.27%
Market Cap26.18M Forward P/E- EPS next Y-0.33 Insider Trans-0.02% Shs Float39.69M Perf Month33.40%
Income-59.49M PEG- EPS next Q-0.14 Inst Own39.38% Short Float0.12% Perf Quarter-32.90%
Sales1.68M P/S15.59 EPS this Y33.57% Inst Trans19.80% Short Ratio0.02 Perf Half Y-65.98%
Book/sh0.88 P/B0.38 EPS next Y29.03% ROA- Short Interest0.05M Perf Year-80.50%
Cash/sh0.96 P/C0.35 EPS next 5Y- ROE- 52W Range0.19 - 2.08 Perf YTD-31.53%
Dividend Est.- P/FCF- EPS past 5Y- ROI-90.47% 52W High-83.97% Beta2.05
Dividend TTM- Quick Ratio6.95 Sales past 5Y- Gross Margin64.84% 52W Low74.42% ATR (14)0.07
Dividend Ex-Date- Current Ratio6.02 EPS Y/Y TTM-190.90% Oper. Margin-3842.97% RSI (14)52.75 Volatility27.45% 15.88%
Employees- Debt/Eq0.26 Sales Y/Y TTM- Profit Margin-3545.47% Recom2.00 Target Price0.65
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q-161.58% Payout- Rel Volume0.35 Prev Close0.35
Sales Surprise-6.38% EPS Surprise0.00% Sales Q/Q- EarningsFeb 29 AMC Avg Volume2.44M Price0.33
SMA2019.44% SMA50-3.24% SMA200-53.91% Trades Volume409,450 Change-4.71%
Date Action Analyst Rating Change Price Target Change
Nov-18-22Initiated BofA Securities Neutral $2
Oct-25-22Initiated Credit Suisse Outperform $5
Sep-06-22Initiated Cowen Outperform
Feb-29-24 04:01PM
Feb-27-24 02:00AM
Feb-26-24 01:51PM
08:47AM
Feb-21-24 04:05PM
09:55AM Loading…
Jan-15-24 09:55AM
Dec-29-23 08:22AM
Dec-21-23 12:00PM
Dec-18-23 08:00AM
Nov-13-23 09:36AM
Nov-09-23 04:02PM
Oct-19-23 12:27PM
Oct-12-23 08:00AM
Oct-06-23 07:00AM
Sep-21-23 08:00AM
03:03AM Loading…
Sep-15-23 03:03AM
Sep-13-23 01:16PM
08:00AM
Aug-14-23 09:26AM
Aug-11-23 06:43AM
Aug-10-23 04:01PM
Jul-10-23 07:00AM
Jun-08-23 01:20PM
Jun-07-23 07:00AM
May-31-23 07:00AM
May-12-23 11:12AM
May-11-23 04:01PM
May-04-23 02:00AM
May-03-23 04:56PM
07:00AM
08:00AM Loading…
Apr-13-23 08:00AM
Mar-13-23 11:51AM
Mar-08-23 08:32AM
Mar-07-23 04:01PM
Feb-08-23 11:37AM
Feb-06-23 07:00AM
Feb-02-23 07:00AM
Jan-06-23 10:43AM
Jan-05-23 07:00AM
Dec-29-22 02:44PM
Dec-27-22 11:05AM
Dec-01-22 07:00AM
Nov-19-22 07:52AM
Nov-10-22 04:01PM
Nov-01-22 11:53AM
Oct-27-22 07:00AM
Oct-19-22 07:00AM
Sep-21-22 07:00AM
Sep-19-22 07:00AM
Aug-22-22 04:08PM
Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its leveraging technologies designed to directly target the brain establishes a new category of medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. The company is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martucci Walter Edward IIChief Executive OfficerSep 11Sale1.052,3532,4713,150,180Sep 14 08:30 AM
Franklin MatthewPresident & COOSep 11Sale1.051,7281,814753,898Sep 14 08:29 AM
Studer JacquelineChief Legal OfficerSep 11Sale1.051,1301,186348,292Sep 14 08:31 AM
Shanbhag SantoshChief Financial OfficerSep 11Sale1.05830872323,636Sep 14 08:28 AM